Clinical aspects of CAG repeat diseases.

Clinical aspects of CAG repeat diseases.

Item
http://www.wikidata.org/entity/Q41527046
Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicityCOPASAAR--a database for proteomic analysis of single amino acid repeats.Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tractGlutamine and Asparagine Side Chain Hyperconjugation-Induced Structurally Sensitive Vibrations.PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.Polyglutamine pathogenesis.The androgen receptor: structure, mutations, and antiandrogens.The clinical and genetic features of Huntington disease.PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond.Antioxidants in Huntington's disease.Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.Androgen receptor gene mutation, rearrangement, polymorphism.Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity.
P2860

Clinical aspects of CAG repeat diseases.

Item
http://www.wikidata.org/entity/Q41527046
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Clinical aspects of CAG repeat diseases.
@en
type
label
Clinical aspects of CAG repeat diseases.
@en
prefLabel
Clinical aspects of CAG repeat diseases.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Clinical aspects of CAG repeat diseases.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1750-3639.1997.TB00892.X
P433
P478
P577
P698